Healthcare >> Analyst Interviews >> March 30, 2023
David Nierengarten, Ph.D., is Managing Director, Equity Research at Wedbush Securities. He has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company helps him succeed in analyzing both science and business models. In addition, Dr. Nierengarten has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. Dr. Nierengarten received his B.S. in Biochemistry from the University of Wisconsin-Madison and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.
Profile
Word count: 2,903
TWST: Since we spoke in 2022, how has the surrounding macro and regulatory environment changed?
Dr. Nierengarten: There’ve been several
